1. Academic Validation
  2. Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine

Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine

  • Cells. 2021 Oct 11;10(10):2715. doi: 10.3390/cells10102715.
Evan R Barry 1 Vladimir Simov 1 Iris Valtingojer 2 Olivier Venier 3
Affiliations

Affiliations

  • 1 Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • 2 Sanofi, 94400 Vitry-sur-Seine, France.
  • 3 Sanofi, 91380 Chilly-Mazarin, France.
Abstract

The Hippo pathway is an evolutionary conserved signaling network that regulates essential processes such as organ size, cell proliferation, migration, stemness and Apoptosis. Alterations in this pathway are commonly found in solid tumors and can lead to hyperproliferation, resistance to chemotherapy, compensation for mKRAS and tumor immune evasion. As the terminal effectors of the Hippo pathway, the transcriptional coactivators YAP1/TAZ and the transcription factors TEAD1-4 present exciting opportunities to pharmacologically modulate the Hippo biology in Cancer settings, inflammation and regenerative medicine. This review will provide an overview of the progress and current strategies to directly and indirectly target the YAP1/TAZ protein-protein interaction (PPI) with TEAD1-4 across multiple modalities, with focus on recent small molecules able to selectively bind to TEAD, block its autopalmitoylation and inhibit YAP1/TAZ-TEAD-dependent transcription in Cancer.

Keywords

Hippo pathway; TEAD binders; TEAD transcription factors; YAP1/TAZ; palmitate pocket.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-147214
    98.49%, pan-TEAD Inhibitor
    YAP
  • HY-134956
    99.94%, YAP/TAZ Inhibitor
    YAP